Astrana Health (NASDAQ:ASTH) Given New $49.00 Price Target at Bank of America

Astrana Health (NASDAQ:ASTH) had its target price trimmed by Bank of America from $55.00 to $49.00 in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

ASTH has been the subject of several other research reports. Robert W. Baird lowered their price target on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday. Truist Financial lowered their target price on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a report on Monday, January 13th. Stifel Nicolaus lowered their target price on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Finally, Macquarie upgraded shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $56.83.

Astrana Health Price Performance

Shares of ASTH opened at $26.78 on Tuesday. Astrana Health has a fifty-two week low of $23.12 and a fifty-two week high of $63.20. The firm’s 50 day moving average price is $34.70 and its 200 day moving average price is $44.31. The company has a market cap of $1.51 billion, a P/E ratio of 20.60, a PEG ratio of 1.37 and a beta of 1.20. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. On average, research analysts forecast that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Institutional Trading of Astrana Health

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Astrana Health by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 4,685,959 shares of the company’s stock valued at $147,748,000 after purchasing an additional 20,757 shares during the last quarter. State Street Corp purchased a new stake in Astrana Health in the 3rd quarter valued at $91,966,000. Dimensional Fund Advisors LP raised its position in Astrana Health by 10.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,045,540 shares of the company’s stock valued at $32,968,000 after purchasing an additional 101,192 shares during the last quarter. Geode Capital Management LLC purchased a new stake in Astrana Health in the 3rd quarter valued at $58,995,000. Finally, 325 Capital LLC raised its position in Astrana Health by 30.3% in the 4th quarter. 325 Capital LLC now owns 886,916 shares of the company’s stock valued at $27,964,000 after purchasing an additional 206,009 shares during the last quarter. Hedge funds and other institutional investors own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.